Français
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
huntington disease/− nicotine
Le lien est enregistré dans le presse-papiers
Page 1 de 19 résultats
4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The present invention relates to 4-hydroxy-4-methyl-piperidine-1-carboxylic acid(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide, which is a compound of formula
##STR00002## and to pharmaceutically acceptable acid addition salts thereof. This compound is generically
Pyridone substituted benzothiazole derivatives
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
The present invention generally relates to pyridone substituted benzothiazole compounds that are adenosine receptor ligands. Specifically, the compounds of the present invention have a good affinity to the A.sub.2A -receptor and a high selectivity to the A.sub.1 - and
Benzathiazol-acetamides
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
Adenosine modulates a wide range of physiological functions by interacting with specific cell surface receptors. The potential of adenosine receptors as drug targets was first reviewed in 1982. Adenosine is related both structurally and metabolically to the bioactive
Aminoadamantane derivatives as therapeutic agents
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et
Aminoadamantane derivatives as therapeutic agents
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et
Aminoadamantane derivatives as therapeutic agents
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et
Benzothiazole derivatives
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
Adenosine modulates a wide range of physiological functions by interacting with specific cell surface receptors. The potential of adenosine receptors as drug targets was first reviewed in 1982. Adenosine is related both structurally and metabolically to the bioactive
Phenyl-substituted nicotinic ligands, and methods of use thereof
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
Neuronal nicotinic acetylcholine receptors (nAChRs) serve a wide range of physiological functions and have been implicated in a number of pathological processes and pharmacological effects of nicotinic drugs. Many of the important in vivo effects of nicotine in the
Phenyl-substituted nicotinic ligands, and methods of use thereof
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
Neuronal nicotinic acetylcholine receptors (nAChRs) serve a wide range of physiological functions and have been implicated in a number of pathological processes and pharmacological effects of nicotinic drugs. Many of the important in vivo effects of nicotine in the
Urea compounds and their use as enzyme inhibitors
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The present invention relates to compounds and their uses, and in particular to compounds and their therapeutic use in the treatment or prevention of conditions having an association with substrates, such as the neurotransmitter anandamide, which are broken down by the fatty
Urea compounds and their use as enzyme inhibitors
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The present invention relates to compounds and their uses, and in particular to compounds and their therapeutic use in the treatment or prevention of conditions having an association with substrates, such as the neurotransmitter anandamide, which are broken down by the fatty
6H-oxazolo[4,5 e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
The invention relates to 6H-oxazolo[4,5-e]indole derivatives of the formula I
##STR00002## in which R.sup.1 is H or Het.sup.1, R.sup.2 is H, A, cycloalkyl, --(CH.sub.2).sub.p--N(R.sup.5).sub.2, --(CH.sub.2).sub.p--OR.sup.5, --(CH.sub.2).sub.n--Ar or --(CH.sub.2).sub.n-Het, R.sup.3 is H, Hal, OH, OA
6H-oxazolo[4,5-e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
The invention relates to 6H-oxazolo[4,5-e]indole derivatives of the formula I
##STR00002## in which
R.sup.1 is H or Het.sup.1,
R.sup.2 is H, A, cycloalkyl, --(CH.sub.2).sub.p--N(R.sup.5).sub.2, --(CH.sub.2).sub.p--OR.sup.5, --(CH.sub.2).sub.n--Ar or --(CH.sub.2).sub.n-Het,
R.sup.3 is H, Hal, OH, OA
Dihydroimidazo[4,5-e]indole and 7h-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
The invention relates to dihydroimidazo[4,5-e]indole and 7H-pyrrolo-[3,2-]quinoxaline derivatives of the formula I
##STR00002## in which A-B-D is --NR.sup.6--CR.sup.2.dbd.N--, --N.dbd.CR.sup.2--NR.sup.6-- or --N.dbd.CR.sup.7--CR.sup.8.dbd.N--, R.sup.1 is H or Het.sup.1, R.sup.2 is H, A, cycloalkyl,
Pyrroloquinoline derivatives as 5-HT.sub.6 antagonists, preparation method and use thereof
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The invention relates to the field of pharmaceutical and organic chemistry, and provides pyrroloquinolone derivatives, formulations and methods.
BACKGROUND ART
Serotonin (5-Hydroxytryptamine; 5-HT) receptors play a critical role in many physiological and behavioral functions
La base de données d'herbes médicinales la plus complète soutenue par la science
- Fonctionne en 55 langues
- Cures à base de plantes soutenues par la science
- Reconnaissance des herbes par image
- Carte GPS interactive - étiquetez les herbes sur place (à venir)
- Lisez les publications scientifiques liées à votre recherche
- Rechercher les herbes médicinales par leurs effets
- Organisez vos intérêts et restez à jour avec les nouvelles recherches, essais cliniques et brevets
Tapez un symptôme ou une maladie et lisez des informations sur les herbes qui pourraient aider, tapez une herbe et voyez les maladies et symptômes contre lesquels elle est utilisée.
* Toutes les informations sont basées sur des recherches scientifiques publiées
